Young at heart: Pioneering approaches to model nonischaemic cardiomyopathy with induced pluripotent stem cells

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Gowran, Aoife ^a   Rasponi, Marco ^b   Visone, Roberta ^b   Nigro, Patrizia ^a   Perrucci, Gianluca L ^c   Righetti, Stefano ^d   Zanobini, Marco ^a   Pompilio, Giulio ^a,c  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b POLITECNICO DI MILANO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GROWTH HORMONE; KRUPPEL LIKE FACTOR 4; LENTIVIRUS VECTOR; OCTAMER TRANSCRIPTION FACTOR 4; ONCOPROTEIN; PENTOXIFYLLINE; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SOX2;

CARDIAC MUSCLE CELL; CELL DIFFERENTIATION; CELL FATE; CELL MATURATION; CELL REPROGRAMMING TECHNIQUE; CULTURE MEDIUM; DISEASE MODEL; HEALTH CARE FACILITY; HEART TRANSPLANTATION; HUMAN; INDUCED PLURIPOTENT STEM CELL; MEDICAL RESEARCH; NONISCHEMIC CARDIOMYOPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; TECHNOLOGY; TREATMENT OUTCOME;

EID: 84964829795     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/4287158     Document Type: Review

References (144)

1. B. J. Maron, J. A. Towbin, G. Thiene, et al., "Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology InterdisciplinaryWorking Groups; and Council on Epidemiology and Prevention, " Circulation, vol. 113, no. 14, pp. 1807-1816, 2006.
2. F. Follath, "Nonischemic heart failure: epidemiology, pathophysiology and progression of disease, " Journal of Cardiovascular Pharmacology, vol. 33, supplement 3, pp. S31-S35, 1999.
3. D. A. Bluemke, "MRI of nonischemic cardiomyopathy, " American Journal of Roentgenology, vol. 195, no. 4, pp. 935-940, 2010.
4. J. A. Franciosa, M. Wilen, S. Ziesche, and J. N. Cohn, "Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy, " The American Journal of Cardiology, vol. 51, no. 5, pp. 831-836, 1983.
5. B. A. Bart, L. K. Shaw, C. B. McCants Jr., et al., "Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy, " Journal of the American College of Cardiology, vol. 30, no. 4, pp. 1002-1008, 1997.
6. F. Follath, "Ischemic versus non-ischemic heart failure: should the etiology be determined?" Heart Failure Monitor, vol. 1, no. 4, pp. 122-125, 2001.
7. B. F. Uretsky, J. B. Young, F. E. Shahidi, L. G. Yellen, M. C. Harrison, and M. K. Jolly, "Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial, " Journal of the American College of Cardiology, vol. 22, no. 4, pp. 955-962, 1993.
8. M. Packer, M. Gheorghiade, J. B. Young, et al., "Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors, " The New England Journal of Medicine, vol. 329, no. 1, pp. 1-7, 1993.
9. K. Malliaras, R. R. Makkar, R. R. Smith, et al., "Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-derived aUtologous stem CElls to reverse ventricular dysfunction), " Journal of the American College of Cardiology, vol. 63, no. 2, pp. 110-122, 2014.
10. M. Tendera, W. Wojakowski, W. Ruyllo, et al., "Intracoronary infusion of bonemarrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: Results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) trial, " European Heart Journal, vol. 30, no. 11, pp. 1313-1321, 2009.
11. S. A. Fisher, D. M. Clifford, S. J. Brunskill, et al., "Stemcell treatment for acute myocardial infarction, " The Cochrane Database of Systematic Reviews, vol. 9, Article IDCD006536, 2015.
12. M. Peruzzi, E. De Falco, A. Abbate, et al., "State of the art on the evidence base in cardiac regenerative therapy: overview of systematic reviews, " BioMed Research International, vol. 2015, Article ID 613782, 7 pages, 2015.
13. S. Maltais, S. J. Joggerst, A. Hatzopoulos, et al., "Stemcell therapy for chronic heart failure: an updated appraisal, " Expert Opinion on Biological Therapy, vol. 13, no. 4, pp. 503-516, 2013.
14. J. A. Thomson, "Embryonic stem cell lines derived fromhuman blastocysts, " Science, vol. 282, no. 5391, pp. 1145-1147, 1998.
15. K. Takahashi and S. Yamanaka, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, " Cell, vol. 126, no. 4, pp. 663-676, 2006.
16. S. R. Braam, L. Tertoolen, A. van de Stolpe, T. Meyer, R. Passier, and C. L. Mummery, "Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes, " Stem Cell Research, vol. 4, no. 2, pp. 107-116, 2010.
17. L. Guo, R. M. C. Abrams, J. E. Babiarz, et al., "Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes, " Toxicological Sciences, vol. 123, no. 1, pp. 281-289, 2011.
18. K. Harris, M. Aylott, Y. Cui, J. B. Louttit, N. C. McMahon, and A. Sridhar, "Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays, " Toxicological Sciences, vol. 134, no. 2, pp. 412-426, 2013.
19. P. W. Burridge, S. Diecke, E. Matsa, A. Sharma, H. Wu, and J. C. Wu, "Modeling cardiovascular diseases with patient-specific human pluripotent stem cell-derived cardiomyocytes, " Methods in Molecular Biology, vol. 1353, pp. 119-130, 2016.
20. H. Fonoudi, H. Ansari, S. Abbasalizadeh, et al., "A universal and robust integrated platform for the scalable production of human cardiomyocytes from pluripotent stem cells, " Stem Cells Translational Medicine, vol. 4, no. 12, pp. 1482-1494, 2015.
21. D. Qin, Y. Xia, and G. M. Whitesides, "Soft lithography for micro-and nanoscale patterning, " Nature Protocols, vol. 5, no. 3, pp. 491-502, 2010.
22. T. Boudou, W. R. Legant, A. Mu, et al., "A microfabricated platform to measure and manipulate the mechanics of engineered cardiac microtissues, " Tissue Engineering Part A, vol. 18, no. 9-10, pp. 910-919, 2012.
23. N. Thavandiran, N. Dubois, A. Mikryukov, et al., "Design and formulation of functional pluripotent stem cell-derived cardiac microtissues, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 49, pp. E4698-E4707, 2013.
24. A. Mathur, P. Loskill, K. Shao, et al., "Human iPSC-based cardiac microphysiological system for drug screening applications, " Scientific Reports, vol. 5, article 8883, 2015.
25. A. Marsano, C. Conficconi, M. Lemme, et al., "Beating heart on a chip: a novel microfluidic platform to generate functional 3D cardiacmicrotissues, " Lab Chip, vol. 16, no. 3, pp. 599-610, 2016.
26. K. Takahashi, K. Tanabe, M. Ohnuki, et al., "Induction of pluripotent stem cells from adult human fibroblasts by defined factors, " Cell, vol. 131, no. 5, pp. 861-872, 2007.
27. J. Yu, M. A. Vodyanik, K. Smuga-Otto, et al., "Induced pluripotent stem cell lines derived from human somatic cells, " Science, vol. 318, no. 5858, pp. 1917-1920, 2007.
28. B.-K. Chou and L. Cheng, "And then there were none: no need for pluripotency factors to induce reprogramming, " Cell Stem Cell, vol. 13, no. 3, pp. 261-262, 2013.
29. J. T. Dimos, K. T. Rodolfa, K. K. Niakan, et al., "Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons, " Science, vol. 321, no. 5893, pp. 1218-1221, 2008.
30. J. Zhang, G. F. Wilson, A. G. Soerens, et al., "Functional cardiomyocytes derived from human induced pluripotent stem cells, " Circulation Research, vol. 104, no. 4, pp. e30-e41, 2009.
31. D. Taura, M. Sone, K. Homma, et al., "Induction and isolation of vascular cells from human induced pluripotent stem cells -brief report, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 7, pp. 1100-1103, 2009.
32. T.-H. Lee, S.-H. Song, K. L. Kim, et al., "Functional recapitulation of smooth muscle cells via induced pluripotent stem cells from human aortic smooth muscle cells, " Circulation Research, vol. 106, no. 1, pp. 120-128, 2010.
33. R. M. Guzzo, J. Gibson, R.-H. Xu, F. Y. Lee, and H. Drissi, "Efficient differentiation of human iPSC-derived mesenchymal stem cells to chondroprogenitor cells, " Journal of Cellular Biochemistry, vol. 114, no. 2, pp. 480-490, 2013.
34. D. Zhang, W. Jiang, M. Liu, et al., "Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulinproducing cells, " Cell Research, vol. 19, no. 4, pp. 429-438, 2009.
35. Z. Song, J. Cai, Y. Liu, et al., "Efficient generation of hepatocytelike cells from human induced pluripotent stem cells, " Cell Research, vol. 19, no. 11, pp. 1233-1242, 2009.
36. T. Sadahiro, S. Yamanaka, and M. Ieda, "Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications, " Circulation Research, vol. 116, no. 8, pp. 1378-1391, 2015.
37. T. Zhou, C. Benda, S. Dunzinger, et al., "Generation of human induced pluripotent stem cells from urine samples, " Nature Protocols, vol. 7, no. 12, pp. 2080-2089, 2012.
38. R. Mohseni, A. Shoae-Hassani, and J. Verdi, "Reprogramming of endometrial adult stromal cells in the presence of a ROCK inhibitor, thiazovivin, could obtain more efficient iPSCs, " Cell Biology International, vol. 39, no. 5, pp. 515-518, 2015.
39. C. Miere, L. Devito, and D. Ilic, "Sendai virus-based reprogramming of mesenchymal stromal/stem cells from umbilical cord whartons jelly into induced pluripotent stem cells, " in Induced Pluripotent Stem (iPS) Cells: Methods and Protocols, vol. 1357 of Methods in Molecular Biology, pp. 33-44, Springer, Berlin, Germany, 2015.
40. T. Seki, S. Yuasa, M. Oda, et al., "Generation of induced pluripotent stem cells fromhuman terminally differentiated circulating T cells, " Cell Stem Cell, vol. 7, no. 1, pp. 11-13, 2010.
41. S. N. Dowey, X. Huang, B.-K. Chou, Z. Ye, and L. Cheng, "Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression, " Nature Protocols, vol. 7, no. 11, pp. 2013-2021, 2012.
42. K. Nishimura, M. Sano, M. Ohtaka, et al., "Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming, " The Journal of Biological Chemistry, vol. 286, no. 6, pp. 4760-4771, 2011.
43. N. Miyoshi, H. Ishii, H. Nagano, et al., "Reprogramming of mouse and human cells to pluripotency using mature microRNAs, " Cell Stem Cell, vol. 8, no. 6, pp. 633-638, 2011.
44. D. Kim, C.-H. Kim, J.-I. Moon, et al., "Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins, " Cell Stem Cell, vol. 4, no. 6, pp. 472-476, 2009.
45. H. Zhou, S. Wu, J. Y. Joo, et al., "Generation of induced pluripotent stem cells using recombinant proteins, " Cell Stem Cell, vol. 4, no. 5, pp. 381-384, 2009.
46. Y. Rais, A. Zviran, S. Geula, et al., "Deterministic direct reprogramming of somatic cells to pluripotency, " Nature, vol. 502, no. 7469, pp. 65-70, 2013.
47. J. Silva and A. Smith, "Capturing pluripotency, " Cell, vol. 132, no. 4, pp. 532-536, 2008.
48. R. A. Young, "Control of the embryonic stem cell state, " Cell, vol. 144, no. 6, pp. 940-954, 2011.
49. J. Shu, C. Wu, Y. Wu, et al., "Induction of pluripotency inmouse somatic cells with lineage specifiers, " Cell, vol. 153, no. 5, pp. 963-975, 2013.
50. N. Montserrat, E. Nivet, I. Sancho-Martinez, et al., "Reprogramming of human fibroblasts to pluripotency with lineage specifiers, " Cell Stem Cell, vol. 13, no. 3, pp. 341-350, 2013.
51. Y. Matsui, K. Zsebo, and B. L. M. Hogan, "Derivation of pluripotential embryonic stem cells frommurine primordial germcells in culture, " Cell, vol. 70, no. 5, pp. 841-847, 1992.
52. J. L. Resnick, L. S. Bixler, L. Cheng, and P. J. Donovan, "Longterm proliferation of mouse primordial germ cells in culture, " Nature, vol. 359, no. 6395, pp. 550-551, 1992.
53. P. Hou, Y. Li, X. Zhang, et al., "Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds, " Science, vol. 341, no. 6146, pp. 651-654, 2013.
54. D. Paull, A. Sevilla, H. Zhou, et al., "Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells, " Nature Methods, vol. 12, no. 9, pp. 885-892, 2015.
55. M. Turner, S. Leslie, N. G. Martin, et al., "Toward the development of a global induced pluripotent stem cell library, " Cell Stem Cell, vol. 13, no. 4, pp. 382-384, 2013.
56. S. Solomon, F. Pitossi, and M. S. Rao, "Banking on iPSC-is it doable and is it worthwhile, " Stem Cell Reviews and Reports, vol. 11, no. 1, pp. 1-10, 2015.
57. D. J. Pappas, P. Gourraud, C. Le Gall, et al., "Proceedings: human leukocyte antigen haplo-homozygous induced pluripotent stem cell haplobank modeled after the california population: evaluatingmatching in amultiethnic and admixed population, " Stem Cells Translational Medicine, vol. 4, no. 5, pp. 413-418, 2015.
58. P. W. Burridge, E. Matsa, P. Shukla, et al., "Chemically defined generation of human cardiomyocytes, " Nature Methods, vol. 11, pp. 855-860, 2014.
59. C. L. Mummery, J. Zhang, E. S. Ng, D. A. Elliott, A. G. Elefanty, and T. J. Kamp, "Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview, " Circulation Research, vol. 111, no. 3, pp. 344-358, 2012.
60. C. Mummery, D. Ward-van Oostwaard, P. Doevendans, et al., "Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells, " Circulation, vol. 107, no. 21, pp. 2733-2740, 2003.
61. X. Lian, J. Zhang, S. M. Azarin, et al., "Directed cardiomyocyte differentiation from human pluripotent stem cells by modulatingWnt/β-catenin signaling under fully defined conditions, " Nature Protocols, vol. 8, no. 1, pp. 162-175, 2013.
62. M. Xin, E. N. Olson, and R. Bassel-Duby, "Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair, " Nature Reviews Molecular Cell Biology, vol. 14, no. 8, pp. 529-541, 2013.
63. S. Tohyama, F. Hattori, M. Sano, et al., "Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes, " Cell Stem Cell, vol. 12, no. 1, pp. 127-137, 2013.
64. I. Huber, I. Itzhaki, O. Caspi, et al., "Identification and selection of cardiomyocytes during human embryonic stem cell differentiation, " The FASEB Journal, vol. 21, no. 10, pp. 2551-2563, 2007.
65. Q. Zhang, J. Jiang, P. Han, et al., "Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals, " Cell Research, vol. 21, no. 4, pp. 579-587, 2011.
66. X. Yang, L. Pabon, and C. E. Murry, "Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes, " Circulation Research, vol. 114, no. 3, pp. 511-523, 2014.
67. M. Ieda, J.-D. Fu, P. Delgado-Olguin, et al., "Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors, " Cell, vol. 142, no. 3, pp. 375-386, 2010.
68. Y.-J. Nam, K. Song, X. Luo, et al., "Reprogramming of human fibroblasts toward a cardiac fate, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 14, pp. 5588-5593, 2013.
69. R. Wada, N. Muraoka, K. Inagawa, et al., "Induction of human cardiomyocyte-like cells from fibroblasts by defined factors, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 31, pp. 12667-12672, 2013.
70. J.-D. Fu, N. R. Stone, L. Liu, et al., "Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state, " Stem Cell Reports, vol. 1, no. 3, pp. 235-247, 2013.
71. J. X. Chen, M. Krane, M.-A. Deutsch, et al., "Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5., " Circulation Research, vol. 111, no. 1, pp. 50-55, 2012.
72. D. Srivastava and M. Ieda, "Critical factors for cardiac reprogramming, " Circulation Research, vol. 111, no. 1, pp. 5-8, 2012.
73. S. A. Morris, P. Cahan, H. Li, et al., "Dissecting engineered cell types and enhancing cell fate conversion via CellNet, " Cell, vol. 158, no. 4, pp. 889-902, 2014.
74. A. Moretti, M. Bellin, A. Welling, et al., "Patient-specific induced pluripotent stem-cell models for long-QT syndrome, " The New England Journal ofMedicine, vol. 363, no. 15, pp. 1397-1409, 2010.
75. J. Ma, L. Guo, S. J. Fiene, et al., "High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents, "American Journal of Physiology-Heart and Circulatory Physiology, vol. 301, no. 5, pp. H2006-H2017, 2011.
76. A. L. Lahti, V. J. Kujala, H. Chapman, et al., "Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture, " Disease Models and Mechanisms, vol. 5, no. 2, pp. 220-230, 2012.
77. I. Itzhaki, L. Maizels, I. Huber, et al., "Modelling the long QT syndrome with induced pluripotent stem cells, " Nature, vol. 471, no. 7337, pp. 225-229, 2011.
78. E. Dick, D. Rajamohan, J. Ronksley, and C. Denning, "Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening, " Biochemical Society Transactions, vol. 38, no. 4, pp. 1037-1045, 2010.
79. Y.-K. Lee, K.-M. Ng, W.-H. Lai, et al., "Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes, " Stem Cell Reviews and Reports, vol. 7, no. 4, pp. 976-986, 2011.
80. A. Novak, L. Barad, N. Zeevi-Levin, et al., "Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation, " Journal of Cellular and Molecular Medicine, vol. 16, no. 3, pp. 468-482, 2012.
81. M. Hoekstra, C. L. Mummery, A. A. M. Wilde, C. R. Bezzina, and A. O. Verkerk, "Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias, " Frontiers in Physiology, vol. 3, article 346, 2012.
82. B. C. Knollmann, "Induced pluripotent stem cell-derived cardiomyocytes: boutique science or valuable arrhythmia model?" Circulation Research, vol. 112, no. 6, pp. 969-976, 2013.
83. N. M. Mordwinkin, P. W. Burridge, and J. C. Wu, "A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards, " Journal of Cardiovascular Translational Research, vol. 6, no. 1, pp. 22-30, 2013.
84. D. Sinnecker, A. Goedel, K.-L. Laugwitz, and A. Moretti, "Induced pluripotent stem cell-derived cardiomyocytes: a versatile tool for arrhythmia research, " Circulation Research, vol. 112, no. 6, pp. 961-968, 2013.
85. S. G. M. Uzel, A. Pavesi, and R. D. Kamm, "Microfabrication and microfluidics for muscle tissue models, " Progress in Biophysics and Molecular Biology, vol. 115, no. 2-3, pp. 279-293, 2014.
86. T. Kofidis, P. Akhyari, J. Boublik, et al., "In vitro engineering of heart muscle: artificial myocardial tissue, " The Journal of Thoracic and Cardiovascular Surgery, vol. 124, no. 1, pp. 63-69, 2002.
87. C. A. Powell, B. L. Smiley, J. Mills, and H. H. Vandenburgh, "Mechanical stimulation improves tissue-engineered human skeletal muscle, " The American Journal of Physiology-Cell Physiology, vol. 283, no. 5, pp. C1557-C1565, 2002.
88. W.-H. Zimmermann, I. Melnychenko, G. Wasmeier, et al., "Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts, " Nature Medicine, vol. 12, no. 4, pp. 452-458, 2006.
89. T. Okano, S. Satoh, T. Oka, and T. Matsuda, "Tissue engineering of skeletal muscle: highly dense, highly oriented hybridmuscular tissues biomimicking native tissues, " ASAIO Journal, vol. 43, no. 5, pp. M749-M753, 1997.
90. W.-H. Zimmermann, K. Schneiderbanger, P. Schubert, et al., "Tissue engineering of a differentiated cardiac muscle construct, " Circulation Research, vol. 90, no. 2, pp. 223-230, 2002.
91. A. Hansen, A. Eder, M. Bonstrup, et al., "Development of a drug screening platform based on engineered heart tissue, " Circulation Research, vol. 107, no. 1, pp. 35-44, 2010.
92. R. Zhao, C. S. Chen, and D. H. Reich, "Force-driven evolution of mesoscale structure in engineered 3D microtissues and the modulation of tissue stiffening, " Biomaterials, vol. 35, no. 19, pp. 5056-5064, 2014.
93. N. L. Tulloch, V. Muskheli, M. V. Razumova, et al., "Growth of engineered human myocardium with mechanical loading and vascular coculture, " Circulation Research, vol. 109, no. 1, pp. 47-59, 2011.
94. S. Schaaf, A. Shibamiya, M. Mewe, et al., "Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology, " PLoS ONE, vol. 6, no. 10, Article ID e26397, 2011.
95. S. S. Nunes, J. W. Miklas, J. Liu, et al., "Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes, " Nature Methods, vol. 10, no. 8, pp. 781-787, 2013.
96. J. W. Miklas, S. S. Nunes, A. Sofla, et al., "Bioreactor for modulation of cardiac microtissue phenotype by combined static stretch and electrical stimulation, " Biofabrication, vol. 6, no. 2, Article ID 024113, 2014.
97. A. F. G. Godier-Furnemont, M. Tiburcy, E. Wagner, et al., "Physiologic force-frequency response in engineered heartmuscle by electromechanical stimulation, " Biomaterials, vol. 60, pp. 82-91, 2015.
98. C. M. Howard and T. A. Baudino, "Dynamic cell-cell and cell-ECM interactions in the heart, " Journal of Molecular and Cellular Cardiology, vol. 70, pp. 19-26, 2014.
99. M. Ieda, "Heart development and regeneration via cellular interaction and reprogramming, " The Keio Journal of Medicine, vol. 62, no. 4, pp. 99-106, 2013.
100. T. A. Baudino, A. McFadden, C. Fix, J. Hastings, R. Price, and T. K. Borg, "Cell patterning: interaction of cardiac myocytes and fibroblasts in three-dimensional culture, " Microscopy and Microanalysis, vol. 14, no. 2, pp. 117-125, 2008.
101. J. W. Nichol, G. C. Engelmayr Jr., M. Cheng, and L. E. Freed, "Co-culture induces alignment in engineered cardiac constructs via MMP-2 expression, " Biochemical and Biophysical Research Communications, vol. 373, no. 3, pp. 360-365, 2008.
102. H. Saini, A. Navaei, A. VanPutten, and M. Nikkhah, "3Dcardiac microtissues encapsulated with the co-culture of cardiomyocytes and cardiac fibroblasts, " Advanced Healthcare Materials, vol. 4, no. 13, pp. 1961-1971, 2015.
103. A. Takeuchi, S. Nakafutami, H. Tani, et al., "Device for co-culture of sympathetic neurons and cardiomyocytes using microfabrication, " Lab on a Chip, vol. 11, no. 13, pp. 2268-2275, 2011.
104. A. Takeuchi, K. Shimba, M. Mori, et al., "Sympathetic neurons modulate the beat rate of pluripotent cell-derived cardiomyocytes in vitro, " Integrative Biology, vol. 4, no. 12, pp. 1532-1539, 2012.
105. A. Takeuchi, K. Shimba, Y. Takayama, et al., "Microfabricated device for co-culture of sympathetic neuron and iPS-derived cardiomyocytes, " in Proceedings of the 35th IEEE Annual International Conference of the Engineering in Medicine and Biology Society (EMBC 13), pp. 3817-3820, IEEE, Osaka, Japan, July 2013.
106. K. Miwa, J.-K. Lee, Y. Takagishi, et al., "Axon guidance of sympathetic neurons to cardiomyocytes by glial cell line-derived neurotrophic factor (GDNF), " PLoS ONE, vol. 8, no. 7, Article ID e65202, 2013.
107. D. L. Brutsaert, "Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity, " Physiological Reviews, vol. 83, no. 1, pp. 59-115, 2003.
108. D. A. Narmoneva, R. Vukmirovic, M. E. Davis, R. D. Kamm, and R. T. Lee, "Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration, " Circulation, vol. 110, no. 8, pp. 962-968, 2004.
109. I. Vollert, M. Seiffert, J. Bachmair, et al., "In vitro perfusion of engineered heart tissue through endothelialized channels, " Tissue Engineering-Part A, vol. 20, no. 3-4, pp. 854-863, 2014.
110. L. L. Y. Chiu, M. Montgomery, Y. Liang, H. Liu, and M. Radisic, "Perfusable branching microvessel bed for vascularization of engineered tissues, " Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 50, pp. E3414-E3423, 2012.
111. L. Ghasemi-Mobarakeh, M. P. Prabhakaran, M. Nematollahi, K. Karbalaie, S. Ramakrishna, and M. H. Nasr-Esfahani, "Embryonic stem cell differentiation to cardiomyocytes on nanostructured scaffolds for myocardial tissue regeneration, " International Journal of Polymeric Materials and Polymeric Biomaterials, vol. 63, no. 5, pp. 240-245, 2014.
112. S. Battista, D. Guarnieri, C. Borselli, et al., "The effect of matrix composition of 3D constructs on embryonic stem cell differentiation, " Biomaterials, vol. 26, no. 31, pp. 6194-6207, 2005.
113. E. Serena, E. Figallo, N. Tandon, et al., "Electrical stimulation of human embryonic stem cells: cardiac differentiation and the generation of reactive oxygen species, " Experimental Cell Research, vol. 315, no. 20, pp. 3611-3619, 2009.
114. N. Tandon, A. Marsano, R. Maidhof, et al., "Surface-patterned electrode bioreactor for electrical stimulation, " Lab on a Chip, vol. 10, no. 6, pp. 692-700, 2010.
115. A. Pavesi, G. Adriani, M. Rasponi, I. K. Zervantonakis, G. B. Fiore, and R. D. Kamm, "Controlled electromechanical cell stimulation on-a-chip, " Scientific Reports, vol. 5, Article ID 11800, 2015.
116. P. Perel, I. Roberts, E. Sena, et al., "Comparison of treatment effects between animal experiments and clinical trials: systematic review, " British Medical Journal, vol. 334, no. 7586, pp. 197-200, 2007.
117. M. Mollova, K. Bersell, S. Walsh, et al., "Cardiomyocyte proliferation contributes to heart growth in young humans, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 4, pp. 1446-1451, 2013.
118. P. J. Kannankeril and D. M. Roden, "Drug-induced long QT and torsade de pointes: recent advances, " Current Opinion in Cardiology, vol. 22, no. 1, pp. 39-43, 2007.
119. L. Carlsson, "In vitro and in vivo models for testing arrhythmogenesis in drugs, " Journal of InternalMedicine, vol. 259, no. 1, pp. 70-80, 2006.
120. N. Sun, M. Yazawa, J. Liu, et al., "Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy, " Science Translational Medicine, vol. 4, no. 130, Article ID 130ra47, 2012.
121. F. Lan, A. S. Lee, P. Liang, et al., "Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells, " Cell Stem Cell, vol. 12, no. 1, pp. 101-113, 2013.
122. D. Ma, H. Wei, J. Lu, et al., "Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy, " European Heart Journal, vol. 34, no. 15, pp. 1122-1133, 2013.
123. O. Caspi, I. Huber, A. Gepstein, et al., "Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells, " Circulation: Cardiovascular Genetics, vol. 6, no. 6, pp. 557-568, 2013.
124. C. Kim, J. Wong, J. Wen, et al., "Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs, " Nature, vol. 494, no. 7435, pp. 105-110, 2013.
125. F. Djouadi, Y. Lecarpentier, J.-L. Hebert, P. Charron, J. Bastin, and C. Coirault, "A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy, " Cardiovascular Research, vol. 84, no. 1, pp. 83-90, 2009.
126. E. Matsa, D. Rajamohan, E. Dick, et al., "Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation, " European Heart Journal, vol. 32, no. 8, pp. 952-962, 2011.
127. C. I. Spencer, S. Baba, K. Nakamura, et al., "Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia, " Stem Cell Reports, vol. 3, no. 2, pp. 269-281, 2014.
128. R. P. Davis, S. Casini, C. W. Van Den Berg, et al., "Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease, " Circulation, vol. 125, no. 25, pp. 3079-3091, 2012.
129. A. Fatima, S. Kaifeng, S. Dittmann, et al., "The disease-specific phenotype in cardiomyocytes derived frominduced pluripotent stem cells of two longQT syndrome type 3 patients, " PLoS ONE, vol. 8, no. 12, Article ID e83005, 2013.
130. M. Yazawa, B. Hsueh, X. Jia, et al., "Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome, " Nature, vol. 471, no. 7337, pp. 230-236, 2011.
131. A. Fatima, G. Xu, K. Shao, et al., "In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells, " Cellular Physiology and Biochemistry, vol. 28, no. 4, pp. 579-592, 2011.
132. C. B. Jung, A. Moretti, M. Mederos y Schnitzler, et al., "Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia, " The EMBO Molecular Medicine, vol. 4, no. 3, pp. 180-191, 2012.
133. X. Carvajal-Vergara, A. Sevilla, S. L. Dsouza, et al., "Patientspecific induced pluripotent stem-cell-derived models of LEOPARD syndrome, " Nature, vol. 465, no. 7299, pp. 808-812, 2010.
134. Y. Jiang, S. Habibollah, K. Tilgner, et al., "An induced pluripotent stem cell model of hypoplastic left heart syndrome (HLHS) reveals multiple expression and functional differences in HLHS-derived cardiac myocytes, " Stem Cells Translational Medicine, vol. 3, no. 4, pp. 416-423, 2014.
135. J. Finsterer and L. Cripe, "Treatment of dystrophin cardiomyopathies, " Nature Reviews Cardiology, vol. 11, no. 3, pp. 168-179, 2014.
136. E. Dick, S. Kalra, D. Anderson, et al., "Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations, " Stem Cells and Development, vol. 22, no. 20, pp. 2714-2724, 2013.
137. S. Zatti, S. Martewicz, E. Serena, et al., "Complete restoration of multiple dystrophin isoforms in genetically corrected Duchenne muscular dystrophy patient-derived cardiomyocytes, " Molecular Therapy-Methods & Clinical Development, vol. 1, 2014.
138. X. Guan, D. L. Mack, C. M. Moreno, et al., "Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery, " Stem Cell Research, vol. 12, no. 2, pp. 467-480, 2014.
139. B. Lin, Y. Li, L. Han, et al., "Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy, " DiseaseModels & Mechanisms, vol. 8, no. 5, pp. 457-466, 2015.
140. J. Y. Wen, C. Wei, K. Shah, J. Wong, C. Wang, and H. V. Chen, "Maturation-based model of arrhythmogenic right ventricular dysplasia using patient-specific induced pluripotent stem cells, " Circulation Journal, vol. 79, no. 7, pp. 1402-1408, 2015.
141. B. T. Darras, D. T. Miller, and D. K. Urion, "Dystrophinopathies, " in GeneReviews(R), R. A. Pagon, M. P. Adam, H. H. Ardinger, et al., Eds., University of Washington, Seattle, Wash, USA, 1993.
142. A. Goyenvalle, G. Griffith, A. Babbs, et al., "Functional correction in mouse models of muscular dystrophy using exonskipping tricyclo-DNA oligomers, " Nature Medicine, vol. 21, no. 3, pp. 270-275, 2015.
143. H. L. Li, N. Fujimoto, N. Sasakawa, et al., "Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9, " Stem Cell Reports, vol. 4, no. 1, pp. 143-154, 2015.
144. K. G. Chen, B. S. Mallon, R. D. G. McKay, and P. G. Robey, "Human pluripotent stemcell culture: considerations for maintenance, expansion, and therapeutics, " Cell Stem Cell, vol. 14, no. 1, pp. 13-26, 2014.